(For-profit organisation)

Silence Therapeutics plc (LSE: SLN) is a biotechnology company and leader dedicated in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases. RNAi is a natural cellular process that occurs in almost all organisms and results in the silencing or shutting down of a target gene protein product. In an effort to combat a wide range of diseases, therapeutics that exploit the RNAi process are being developed to halt the production of disease-causing proteins.

The targeting, delivery and on-going structural modification of sequences are the three platforms for Silence Therapeutics’s RNAi therapeutic development. These three platforms are:
-proprietary delivery using nanoparticles and lipoplex technology;
-proprietary short interfereing RNA (siRNA) sequences complied using bioinformatics algorithms and -scientific research;
-development of siRNA structural features.

Silence Therapeutics develops these structural modifications using three exclusive licences from the University of Massachusetts.

Website

Year established